Cargando…

The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis

Although erythropoietin-stimulating agents are effective in treating anemia in patients with end-stage kidney disease (ESKD) undergoing hemodialysis, some ESKD patients, especially those with inflammation, continue to suffer from anemia. Statin, an inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Meng-Hsu, Su, Fu-You, Chang, Hao-Yun, Su, Po-Cheng, Chiu, Li-Yun, Nowicki, Michal, Kao, Chih-Chin, Lin, Yen-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317421/
https://www.ncbi.nlm.nih.gov/pubmed/35887674
http://dx.doi.org/10.3390/jpm12071175
_version_ 1784755052454346752
author Tsai, Meng-Hsu
Su, Fu-You
Chang, Hao-Yun
Su, Po-Cheng
Chiu, Li-Yun
Nowicki, Michal
Kao, Chih-Chin
Lin, Yen-Chung
author_facet Tsai, Meng-Hsu
Su, Fu-You
Chang, Hao-Yun
Su, Po-Cheng
Chiu, Li-Yun
Nowicki, Michal
Kao, Chih-Chin
Lin, Yen-Chung
author_sort Tsai, Meng-Hsu
collection PubMed
description Although erythropoietin-stimulating agents are effective in treating anemia in patients with end-stage kidney disease (ESKD) undergoing hemodialysis, some ESKD patients, especially those with inflammation, continue to suffer from anemia. Statin, an inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase with lipid-lowering effects, may have a pleiotropic effect in reducing inflammation, and thus increase hemoglobin (Hb) level. We searched the PubMed, Embase, and Cochrane databases for relevant studies. The population of interest comprised advanced chronic kidney disease (CKD) patients and ESKD patients receiving hemodialysis with statin treatment. The included study designs were randomized control trial/cohort study/pre-post observational study, and outcomes of interest were Hb, erythropoietin resistance index (ERI) and ferritin. PRISMA 2020 guidelines were followed, and risk of bias (RoB) was assessed using the RoB 2.0 tool in randomized controlled trials, and the Newcastle-Ottawa scale (NOS) in cohort studies. We eventually included ten studies (5258 participants), comprising three randomized controlled trials and seven cohort studies. Overall, Hb increased by 0.84 g/dL (95% confidence interval [CI]: −0.02 to 1.70) in all groups using statins, including single-arm cohorts, and by 0.72 g/dL (95% CI: −0.02 to 1.46) in studies with placebo control. Hb levels were higher in the study group than in the control group, with a mean difference of 0.18 g/dL (95% CI: 0.04–0.32) at baseline and 1.0 g/dL (95% CI: 0.13–1.87) at the endpoint. Ferritin increased by 9.97 ng/mL (95% CI: −5.36 to 25.29) in the study group and decreased by 34.01 ng/mL (95% CI: −148.16 to 80.14) in the control group; ferritin fluctuation was higher in the control group. In conclusion, statin may improve renal anemia in ESKD patients receiving hemodialysis and regular erythropoietin-stimulating agents. Future studies with more rigorous methodology and larger sample size study should be performed to confirm this beneficial effect.
format Online
Article
Text
id pubmed-9317421
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93174212022-07-27 The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis Tsai, Meng-Hsu Su, Fu-You Chang, Hao-Yun Su, Po-Cheng Chiu, Li-Yun Nowicki, Michal Kao, Chih-Chin Lin, Yen-Chung J Pers Med Article Although erythropoietin-stimulating agents are effective in treating anemia in patients with end-stage kidney disease (ESKD) undergoing hemodialysis, some ESKD patients, especially those with inflammation, continue to suffer from anemia. Statin, an inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase with lipid-lowering effects, may have a pleiotropic effect in reducing inflammation, and thus increase hemoglobin (Hb) level. We searched the PubMed, Embase, and Cochrane databases for relevant studies. The population of interest comprised advanced chronic kidney disease (CKD) patients and ESKD patients receiving hemodialysis with statin treatment. The included study designs were randomized control trial/cohort study/pre-post observational study, and outcomes of interest were Hb, erythropoietin resistance index (ERI) and ferritin. PRISMA 2020 guidelines were followed, and risk of bias (RoB) was assessed using the RoB 2.0 tool in randomized controlled trials, and the Newcastle-Ottawa scale (NOS) in cohort studies. We eventually included ten studies (5258 participants), comprising three randomized controlled trials and seven cohort studies. Overall, Hb increased by 0.84 g/dL (95% confidence interval [CI]: −0.02 to 1.70) in all groups using statins, including single-arm cohorts, and by 0.72 g/dL (95% CI: −0.02 to 1.46) in studies with placebo control. Hb levels were higher in the study group than in the control group, with a mean difference of 0.18 g/dL (95% CI: 0.04–0.32) at baseline and 1.0 g/dL (95% CI: 0.13–1.87) at the endpoint. Ferritin increased by 9.97 ng/mL (95% CI: −5.36 to 25.29) in the study group and decreased by 34.01 ng/mL (95% CI: −148.16 to 80.14) in the control group; ferritin fluctuation was higher in the control group. In conclusion, statin may improve renal anemia in ESKD patients receiving hemodialysis and regular erythropoietin-stimulating agents. Future studies with more rigorous methodology and larger sample size study should be performed to confirm this beneficial effect. MDPI 2022-07-19 /pmc/articles/PMC9317421/ /pubmed/35887674 http://dx.doi.org/10.3390/jpm12071175 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tsai, Meng-Hsu
Su, Fu-You
Chang, Hao-Yun
Su, Po-Cheng
Chiu, Li-Yun
Nowicki, Michal
Kao, Chih-Chin
Lin, Yen-Chung
The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
title The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
title_full The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
title_fullStr The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
title_full_unstemmed The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
title_short The Effect of Statin on Anemia in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
title_sort effect of statin on anemia in patients with chronic kidney disease and end-stage kidney disease: a systematic review and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317421/
https://www.ncbi.nlm.nih.gov/pubmed/35887674
http://dx.doi.org/10.3390/jpm12071175
work_keys_str_mv AT tsaimenghsu theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT sufuyou theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT changhaoyun theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT supocheng theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT chiuliyun theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT nowickimichal theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT kaochihchin theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT linyenchung theeffectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT tsaimenghsu effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT sufuyou effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT changhaoyun effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT supocheng effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT chiuliyun effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT nowickimichal effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT kaochihchin effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis
AT linyenchung effectofstatinonanemiainpatientswithchronickidneydiseaseandendstagekidneydiseaseasystematicreviewandmetaanalysis